 | |
 Taisho Pharmaceutical head office building | |
Native name | 大正製薬ホールディングス株式会社 |
|---|---|
Romanized name | Taishō Seiyaku Hōrudingusu kabushiki gaisha |
| Company type | Public KK |
| TYO: 4581 | |
| ISIN | JP3442850008 |
| Industry | Pharmaceutical |
| Founded | October 12, 1912 |
| Headquarters | Toshima-ku, Tokyo 170-8655 , Japan |
Area served | Worldwide |
Key people | Akira Uehara (President and CEO) |
| Products | |
| Revenue |  JPY 280 billion (FY 2017)
(US$ 2.6 billion) (FY 20177) |
| JPY 31.6 billion (FY 2017)
(US$ 298 million) (FY 2017) | |
| Owner | Uehara family (33.52%) |
Number of employees | 6,340 (consolidated, as of March 31, 2018) |
| Website | www.taisho.co.jp |
| Footnotes / references [1][2][3] | |
Taisho Pharmaceutical Co., Ltd. (大正製薬株式会社, Taishō Seiyaku Kabushiki-gaisha), commonly known as Taisho, is a Japanese multinational pharmaceutical company based in Tokyo.[3]
- ^ "Corporate Data". Taisho Pharmaceutical. Retrieved March 6, 2019.
- ^ "About the company". Financial Times. Retrieved March 6, 2019.
- ^ a b "Company Profile". Nikkei Asian Review. Nikkei Inc. Retrieved March 6, 2019.